MEI Pharma Balance Sheet Health
Financial Health criteria checks 4/6
MEI Pharma has a total shareholder equity of $24.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $27.8M and $2.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$26.91m |
Equity | US$24.88m |
Total liabilities | US$2.87m |
Total assets | US$27.75m |
Recent financial health updates
We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely
May 18We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn Rate
Nov 04Recent updates
New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)
Feb 17Increases to CEO Compensation Might Be Put On Hold For Now at MEI Pharma, Inc. (NASDAQ:MEIP)
Dec 30Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)
Nov 19We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely
May 18Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022
Mar 26Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts
Feb 12MEI Pharma: Another PI3K Delta Progressing To The FDA
Feb 01Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates
Dec 02We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn Rate
Nov 04MEI Pharma EPS misses by $0.12, misses on revenue
May 06MEI Pharma promotes Richard Ghalie to chief medical officer
Apr 30MEI Pharma shares rise 4% as Wells Fargo says voruciclib undervalued
Apr 26The Independent Non-Executive Director of MEI Pharma, Inc. (NASDAQ:MEIP), Frederick Driscoll, Just Sold 40% Of Their Holding
Feb 25New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)
Feb 11Financial Position Analysis
Short Term Liabilities: MEIP's short term assets ($27.7M) exceed its short term liabilities ($2.9M).
Long Term Liabilities: MEIP has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: MEIP is debt free.
Reducing Debt: MEIP has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MEIP has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MEIP has less than a year of cash runway if free cash flow continues to reduce at historical rates of 18.9% each year
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/26 11:03 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MEI Pharma, Inc. is covered by 14 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Stephen V. Byrne | BofA Global Research |
Jonathan Aschoff | Brean Capital |
Gene Mack | Brean Capital |